实用肝脏病杂志 ›› 2011, Vol. 14 ›› Issue (4): 321-324.doi: 10.3969/j.issn.1672-5069.2011.04.037
• 会议纪要 • 上一篇
段晓燕,范建高
收稿日期:2011-03-21
出版日期:2011-08-10
发布日期:2016-04-15
通讯作者:
范建高，E-mail: fanjiangao@gmail.com
作者简介:段晓燕 女，32岁，博士研究生，住院医师。主要从事脂肪肝和肝癌的基础研究。
Received:2011-03-21
Online:2011-08-10
Published:2016-04-15
段晓燕,范建高. 2010 年AASLD年会脂肪性肝病纪要[J]. 实用肝脏病杂志, 2011, 14(4): 321-324.
| [1] CSAK T，GANZ M，KODYS K，et al. Inflammasome activation occurs in NASH in vivo and it is mediated by fatty acids through sensitization to LPS-induced inflammasome activation in hepatocytes[J]. Hepatology，2010，52（S1）:77A. [2] ZHANG Y，LIU SH，LEE CH，et al. Mice lacking thioesterase superfamily member1（THEM1）/STARD14 are protected against diet-induced hepatic steatosis: role of white adipose inflammation[J]. Hepatology，2010，52（S1）:1043A-1044A. [3] KAMADA Y，KISO S，YOSHIDA Y，et al. Estrogen deficiency enhanced the progression of steatohepatitis with increased macrophage infiltration in mice fed with high fat and high cholesterol diet[J]. Hepatology，2010，52（S1）:1051A. [4] BANZ V，CLARIDGE LC，KAVANAGH DP，et al. Kupffer cell dependent IL-17 secretion and Th17 cell recruitment drives murine steatohepatitis[J]. Hepatology，2010，52（S1）:1045A-1046A. [5] THAPALIYA S，BERK MP，DIXON LJ，et al. Role of BAX activation in steatohepatitis development in vivo[J]. Hepatology， 2010，52（S1）:1048A. [6] DIXON LJ，BERK MP，THAPALIYA S，et al. Caspase 1-mediated regulation of fibrogenesis in diet-induced steatohepatitis[J]. Hepatology，2010，52（S1）:77A. [7] RANGWALA F，GUY CD，JIUYI LU，et al. increased production of sonic hedgehog by ballooned hepatocytes: implications for fibrosis progression in NASH[J]. Hepatology，2010，52（S1）:78A. [8] KUMAMOTO R，UTO H，TANOUE S，et al. Dietary fructose rather than dietary fat affects liver tumor incidence induced by diethylnitrosamine administration in rats[J]. Hepatology，2010，52（S1）:1042A. [9] SYDOR S，GU Y，SOWA JP，et al. Western diet enhances expression of death receptors and fatty acid transporters in a mouse model of 70% hepatectomy and leads to increased cell proliferation in the liver[J]. Hepatology，2010，52（S1）:1056A. [10] IKEJIMA K，YAMAGATA H，ARAI K，et al. Depletion of natural killer T cells increases the susceptibility to dietary-induced steatohepatitis in mice[J]. Hepatology，2010，52（S1）:1041A. [11] SAWADA K，OHTAKE T，HASEBE T，et al. Disturbance of hepatic and intestinal Toll-like receptor signal pathway in high-fat diet induced NAFLD model mice[J]. Hepatology， 2010，52（S1）:1061A-1062A. [12] JI C，LAU MY，PETROVIC LM，et al. liver specific deletion of the key chaperone GRP78/BIP aggravates a spectrum of acute and chronic stress-induced liver injury[J]. Hepatology，2010，52（S1）:78A. [13] SOON RK，YAN JS，GRENERT JP，et al. Stress signaling in the methionine-choline-deficient model of murine fatty liver disease[J]. Hepatology，2010，52（S1）:1043A. [14] KON K，IKEJIMA K，SAITO H，et al. Trans-fatty acid induces apoptosis of hepatocytes by enhancement of oxidative stress in steatotic liver of KK-AY mice[J]. Hepatology，2010，52（S1）: 1053A-1054A. [15] BAFFY G，NEUSCHWANDER-TETRI BA. Genetics and environment in the progression of NAFLD[J]. Hepatology， 2010，52（S1）:110A [16] DASARATHY S，YANG Y，RUNKANA A，et al. Differential effects of diet and genetic background on hepatic microRNA expression in diet induced NAFLD[J]. Hepatology，2010，52（S1）: 1058A-1059A. [17] PASRICHA S，KENNEY-HUNT J，CHEVERUD J，et al. Quantitative trait loci（QTL）analysis of fatty liver disease[J]. Hepatology，2010，52（S1）:1054A. [18] FRANCQUE S，VERLINDEN W，BROSIUS I，et al. Vascular hyporeactivity in steatosis-induced portal hypertension is mediated by a special cyclooxygenase 2-related mechanism[J]. Hepatology，2010，52（S1）:1040A-1041A. [19] COULON SH，GEERTS AM，CASTELEYN C，et al. Presence of liver angiogenesis and upregulation of VEGF in a mice model of non-alcoholic steatohepatitis（NASH）[J]. Hepatology，2010，52（S1）:1062A-1063A. [20] BUCK M，CHOJKIER M. TNF-α induced phosphorylation of C/EBPβ serine-239 is critical for the development of obesity and fatty liver[J]. Hepatology，2010，52（S1）:77A. [21] MOYLAN CA，ABDELMALEK MF，PANG H，et al. Signals from the fibrostic liver in patients with NAFLD may promote diabetes and obesity[J]. Hepatology，2010，52（S1）:1049A-1050A. [22] LANTHIER N，MOLENDI-COSTE O，CANI PD，et al. Cross-talk between kupffer cells and adipose tissue in the pathogenesis of IR[J]. Hepatology，2010，52（S1）:1045A. [23] STOLL JM，SHRESTHA S，SCAPA EF，et al. Resistance to diet induced diabetes due to reduced hepatic glucose production in mice lacking phosphatidylcholine transfer protein（PC-TP）[J]. Hepatology，2010，52（S1）:1053A. [24] SONG M，SCHUSCHKE D，ZHOU Z，et al. High fructose feeding induces copper deficiency: a novel mechanism for obesity related fatty liver[J]. Hepatology，2010，52（S1）:1058A. [25] SIDDIQUI MS，SIDDIQUI MB，GREEN RM. Metabolic syndrome resistant A/J mice fed a high fat diet down regulate SREBP-1c activity and function[J]. Hepatology，2010，52（S1）:1063A. [26] SYN WK，CHOI SS，LIASKOU E，et al. osteopontin promotes NAFLD progression[J]. Hepatology，2010，52（S1）:77A. [27] SKOIEN R，POWELL EE， MELINO M，et al. Fatty acids induce hepatocyte senescene in vitro: implications for pathogenesis in NASH[J]. Hepatology，2010，52（S1）:1044A-1045A. [28] KANURI G，SPRUSS A，WAGNERBERGER S，et al. Critical role of plasminogen activator inhibitor（PAI-1），microsomal triglyceride transfer protein（MTTP）and NKT cells in the onset of fructose-induced steatosis in mice[J]. Hepatology，2010，52（S1）:1049A. [29] ARIAZU E，LEUNG TM，PAGANOS S，et al. SPP1 contributer to NASH in mice fed a methionine-choline deficient diet[J]. Hepatology，2010，52（S1）:1053A. [30] KANG HW，COHEN DE. Interactions between thioesterase superfamily member 2（THEM2）and phosphatidylcholine transfer protein（PC-TP）limit hepatic triglyceride secretion[J]. Hepatology，2010，52（S1）:1056A. [31] SYDOR S，SOWA JP，TRECKMANN J，et al. Increased expression of FABP-1 and CFLIPL by free fatty acid treatment is associated with reduced death-receptor mediated apoptosis and ERK-activation in human primary hepatocytes[J]. Hepatology， 2010，52（S1）:1056A-1057A. [32] ZUfiIGA S，FIRRINCIELI D，LASNIER E，et al. Invalidation of the vitamin D nuclear receptor promotes liver steatosis[J]. Hepatology，2010，52（S1）:1021A-1119A. [33] LOKMAN KA，PLEVRIS-PAPAIOANNOU A，BAREN JP，et al. The effect of free fatty acid and reactive oxygen species on CIDEB expression in in vitro model of steatosis[J]. Hepatology，2010，52（S1）:1059A-1060A. [34] SOFTIC S，KIRBY M，SHROYER N，et al. Insulin signaling mediates hepatic steatosis through fatty acid transport proteins （FATPS）in a U-shaped dose dependent manner[J]. Hepatology，2010，52（S1）:1060A. [35] IMAJO K，FUJITA K，NOZAKI Y，et al. Decrease in hepatic microsomal triglyceride transfer protein mRNA levels and pathological progression induced by lipopolysaccharide in a murine NASH model[J]. Hepatology，2010，52（S1）:1060A-1061A. [36] VIKER K，KRISHNAN A，SANDERSON SO，et al. The fast food diet mouse-a novel small animal model of NASH with progressive fibrosis and high fidelity to the human condition[J]. Hepatology，2010，52（S1）:1046A-1047A. [37] WU J，SCHIE IW，VEMURI M，et al. A new mouse model of NASH created by feeding diet containing conjugated linoleic acid[J]. Hepatology，2010，52（S1）:1057A. [38] FOLLI F，CHAVEZ A，CASIRAGHI F，et al. The baboon as a model of NAFLD. Increased intra-hepatic fat content and impairment in the insulin signaling cascade in obese/IR non-human primates[J]. Hepatology，2010，52（S1）:1059A. [39] GUPTA NA，KWUN J，KIRK AD，et al. Role of GLP-1R agonists in decreasing hepatic steatosis and apoptosis in ob/ob mice undergoing ischemia reperfusion injury[J]. Hepatology， 2010，52（S1）:1041A-1042A. [40] RECTOR RS， UPTERGROVE G，MORRIS M，et al. Attenuation of weight gain through daily exercise versus caloric restriction and prevention of NAFLD in hyperphagic OLETF rats[J]. Hepatology，2010，52（S1）:1042A. [41] SOLFIS-MUFOOZ P，GARCA-RUIZ I，GMEZ-IZQUIERDO E，et al. Effects of melatonin on the mitochondrial respiratory chain（MRC）complexes and liver histology in ob/ob mice with NAFLD[J]. Hepatology，2010，52（S1）:1043A. [42] UENO T，NAKAMURA A，NAKAMURA T，et al. Adiponectin suppresses endoplasmic reticulum（ER）stress in nonalcoholic steatohepatitis（NASH）[J]. Hepatology，2010，52（S1）:1044A. [43] LIANG M，PECORA BS，WANG X，et al. Raltegravir prevents hepatic steatosis due to HIV protease inhibitors by enhancing autophagy[J]. Hepatology，2010，52（S1）:1046A. [44] OKADA Y，NISHIKAWA T，JO M，et al. Rosuvastatin improves hepatic inflammation and fibrosis through the inhibition of oxidative stress in rats NASH model[J]. Hepatology，2010，52（S1）: 1047A. [45] ADAR T，LICHTENSTEIN Y，LALAZAR G，et al. Induction of CD4+CD25+FOXP3+ regulatory T cells by oral administration of IgG-enhanced colostrum suppressed the chronic inflammatory state in ob/ob mice alleviating the insulin resistance and liver injury[J]. Hepatology，2010，52（S1）:1047A. [46] MELLS JE，FU PP，HANDY JA，et al. Daily administration of liraglutide ameliorates the deleterious effects of high-fructose corn syrup and trans-fat feeding in C57BL6 mice-implications for NAFLD[J]. Hepatology，2010，52（S1）: 1048A. [47] SALAMONE F，VOLTI GL. Silybin improves liver injury and adipose tissue inflammation in mice with NAFLD[J]. Hepatology，2010，52（S1）:1049A. [48] TREVASKIS JL，GRIFFIN P，WITTMER C，et al. Glucagon-like peptide-1（GLP-1）receptor agonism improves biochemical and histopathological indices of NASH in mice[J]. Hepatology，2010，52（S1）:1061A. [49] LAVALLARD V，BONNAFOUS S，ROUSSEAU D，et al. Role of autophagy in hepatocyte death in NASH[J]. Hepatology，2010，52（S1）:1050A-1051A. [50] MAZO DF，PEREIRA IV，LIMA VM，et al. S-nitroso-N-acetylcysteine （SNAC），a nitric oxide donor，modulated hepatic stellate cells（HSCS）activity and has antifibrogenic properties in experimental nonalcoholic steatohepatitis（NASH）[J]. Hepatology，2010，52（S1）:1052A. [51] DERDAK Z，VILLEGAS KA，WANDS JR. The P53 inhibitor， pifithrin-alpha P-nitro attenuates NAFLD in mice[J]. Hepatology，2010，52（S1）:1052A. [52] ADAR T，LALAZAR G，ZOLOTAROV L，et al. Increased AKT phosphorylation alleviates insulin resistance and its associated liver injury: a synergistic effect of oral insulin and beta glycolipid[J]. Hepatology，2010，52（S1）:1054A-1055A. [53] KAJIKAWA S，IMADA K，TAKEUCHI T，et al. The therapeutic effect of eicosapentaenoic acid against hepatic fibrosis in a rat model of NASH[J]. Hepatology，2010，52（S1）:1055A. [54] LEE JI， LEE JW，KIM YS，et al. Effect of sylimarin on methinnie-choline deficient diet induced NASH in IR rats[J]. Hepatology，2010，52（S1）:1055A. [55] MALHI H，KROPP E，KAUFMAN RJ. C/EBP homologous protein（CHOP）protects mice from NASH[J]. Hepatology，2010，52（S1）:1057A. [56] ADAR T，ZOLOTAROV L，LALAZAR G，et al. Steroid induced insulin resistance and its associated liver injury can be reversed by beta-glucosylceramide. A novel hepatoprotective co-adjuvant treatment strategy for steatohepatitis[J]. Hepatology， 2010，52（S1）:1057A-1058A. [57] TREVASKIS JL，GRIFFIN P，TATARKIEWICZ K，et al. Exenatide exhibits significant antisteatotic actions in diabetic LEPOB/LEPOB mice compared to sitagliptin and pioglitazo-ne[J]. Hepatology，2010，52（S1）:1050A. [58] JUN DW，CHO WK，KWON HJ，et al. Prevention of free fatty acid induced hepatic lipotoxicity by carnitine through restoration of mitochondrial dysfunction[J]. Hepatology，2010，52（S1）: 1062A. [59] SETSHEDI M，TONG M，FENG D，et al. Ceramide inhibitors and PPAR agonists ameliorate alcohol-induced steatohepatitis in an ex-vivo liver slice culture model[J]. Hepatology，2010，52（S1）:1063A. [60] HAN Y，JING Q，FRANCIS H，et al. Emerging roles of microRNAs in the control of apoptosis and transformation in hepatobiliary cells during alcoholic liver disease[J]. Hepatology， 2010，52（S1）:379A. [61] LIN CW，TSAI MH，CHEN X，et al. Enhanced autophagy alleviated ethanol-induced fatty liver in mouse[J]. Hepatology， 2010，52（S1）:379A-380A. [62] AMBADE A，CATALANO D，MANDREKAR P. Targeting HSP90，a molecular chaperone in alcoholic liver injury: inhibition of LPS-induced TNFα production[J]. Hepatology，2010，52（S1）:380A. [63] LEVIN I，NATH B，KURT-JONES EA，et al. Activation of hypoxia inducible factor 1-alpha in hepatocytes requires toll like receptor 4 dependent pathways and results in steatosis in a mouse model of chronic ethanol challenge[J]. Hepatology，2010，52（S1）:380A-381A. [64] DERDAK Z，VILLEGAS KA，WANDS JR. Fibrosis-related transcription factor early growth response-1（EGR-1）promotes steatosis in the liver of ethanol-fed long-evans rats by activating sterol regulatory element binding protein-1（SREBP1）[J]. Hepatology，2010，52（S1）:1112A. [65] KIRPICH I，ZHANG JW，GOBEJISHVILI L，et al. Binge alcohol-induced microvesicular liver steatosis and injury are associated with down-regulation of hepatic HDACS 1，7，9，10，11 and up-regulation of HDAC 3[J]. Hepatology，2010，52（S1）:1113A. [66] HOWARTH DL，SADLER KC. ATF-6 and the unfolded protein response play a key role in acute ethanol-induced steatosis in zebrafish[J]. Hepatology，2010，52（S1）:1113A. [67] DEGRFI D，LEMMERS A，GUSTOT T，et al. Correlation between CCL2（MCP-1），neutrophils recruitment and disease severity in alcoholic hepatitis: a potential IL-17 dependent pathway[J]. Hepatology，2010，52（S1）:1113A-1114A. [68] KI SH，PARK O，ZHENG MQ，et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic plus binge ethanol feeding: role of STAT3[J]. Hepatology，2010，52（S1）:1115A. [69] TR?PO E，GUSTOT T，DEGRE D，et al. Common polymorphism in PNPLA3 gene in associated with stetosis and cirrhosis in alcoholic liver disease[J]. Hepatology，2010，52（S1）:381A. [70] LOUVET A，ARTRU F，WARTEL F，et al. Long-term data in severe alcoholic hepatitis: alcohol relapse is the key factor of survival[J]. Hepatology，2010，52（S1）:381A. [71] ALTAMIRANO J，BATALLER R，FAGUNDES C，et al. Acute kidney injury（AKI）negatively impacts short-term survival in patients with alcoholic hepatitis: implications for therapy[J]. Hepatology，2010，52（S1）:1108A. [72] LOUVET A，ARTRU F，DIAZ E，et al. Prognostic scores are efficient in patients with severe alcoholic hepatitis treated with corticosteroids: comparison of available models[J]. Hepatology， 2010，52（S1）:1108A-1109A. [73] LOUVET A，ARTRU F，WARTEL F，et al. A response-guided therapy for a better management of patients severe alcoholic hepatitis treated with corticosteroids[J]. Hepatology，2010，52（S1）:1109A. [74] HIRAMINE Y，IMAMURA Y，UTO H，et al. Alcohol drinking patients and the risk of fatty liver in Japanese men[J]. Hepatology，2010，52（S1）:1109A-1110A. [75] AMATHIEU R，NAHON P，TRIBA MN，et al. Metabolomic approach by proton NMR spectroscopy of blood serum for the assessment of chronic liver failure in alcoholic cirrhosis patients[J]. Hepatology，2010，52（S1）:1110A. [76] ELLEFSON WM，LAKNER AM，MCKILLOP LH，et al. Hormonal imprinting influences early alcohol-induced liver injury[J]. Hepatology，2010，52（S1）:1110A-1111A. [77] LOUVET A，DELTENRE P，ARTRU F，et al. Hepatic venous pressure gradient in severe alcoholic hepatitis is not associated with survival:a prospective study[J]. Hepatology，2010，52（S1）:1119A. [78] ASRANI SK，LARSON JJ，BENSON JT，et al. Survival of patients with alcoholic hepatitis: a population-based study[J]. Hepatology，2010，52（S1）:1111A. [79] SINGAL AK，ANDERSON KE，KUO YF. Hepatitis C virus infection and increased severity of acute alcoholic hepatitis in a large national inpatient data sample[J]. Hepatology，2010，52（S1）:1112A. [80] THULUVATH PJ，NGUYEN GC. Impact of HCV and hepatic encephalopathy on the outcome of patients admitted with alcoholic hepatitis[J]. Hepatology，2010，52（S1）:1114A. [81] LIANGPUNSAKUL S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States[J]. Hepatology，2010，52（S1）:1114A. |
| [1] | 任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807. |
| [2] | 李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851. |
| [3] | 邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855. |
| [4] | 张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663. |
| [5] | 延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究*[J]. 实用肝脏病杂志, 2019, 22(4): 518-521. |
| [6] | 张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525. |
| [7] | 谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529. |
| [8] | 符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380. |
| [9] | 王海舫, 杨大伟, 贾蓓, 张岁, 柳立平, 马文波, 解从君, 刘明书. 营养支持联合美他多辛治疗酒精性肝病患者肝功能和外周血细胞参数的变化[J]. 实用肝脏病杂志, 2019, 22(3): 381-384. |
| [10] | 朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456. |
| [11] | 张岱,王炳元. 酒精性肝炎的诊断与挑战*[J]. 实用肝脏病杂志, 2019, 22(2): 153-155. |
| [12] | 孙韬华,刘振胜,辛永宁. 酒精性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 156-159. |
| [13] | 霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247. |
| [14] | 苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296. |
| [15] | 谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
